448 RESPONSE-GUIDED THERAPY WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN REDUCES DURATION IN NAIVE AND PEGINTERFERON ALFA-2B/RIBAVIRIN PREVIOUS-TREATMENT-FAILURE PATIENTS WITH HCV GENOTYPE 1

Figure 2. BDI.By both methods, depression was usually identified by Week 12, was related to CR2b dose, and was frequent on 640ug CR2b and PEG2b (25-35%).The two lower doses of CR2b had lower rates of depression by both methods.Multivariate analysis showed BDI scores >20 (moderate depression) were associated with lower rates of viral negativity at end of treatment; SVR12 data appear to be equivalent for all four doses (data not shown).Conclusions: Depression was a common problem by Week 12 on PEG2b and on the highest dose of CR2b (640 ug) whether measured by clinic visits or BDI self-report.The lower rates of depression on 320ug and 480ug CR2b evident through Week 48 may offer an important advance in the treatment of HCV.Final 72-week results will be presented at the meeting.